Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

A patient with a rare, aggressive, blastic plasmacytoid dendritic-cell neoplasm had tumor cells overexpressing BCL2 and had a response with a durable remission to venetoclax, a BCL2 inhibitor.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 379; no. 15; pp. 1479 - 1481
Main Authors:	Agha, Mounzer E, Monaghan, Sara A, Swerdlow, Steven H
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 11-10-2018
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Bone marrow Bortezomib - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Dendritic cells Dendritic Cells - pathology Female Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Humans Medical prognosis Middle Aged Positron Emission Tomography Computed Tomography Remission Simvastatin - therapeutic use Skin Neoplasms - drug therapy Skin Neoplasms - pathology Sulfonamides - therapeutic use Tomography Tumor cells Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A patient with a rare, aggressive, blastic plasmacytoid dendritic-cell neoplasm had tumor cells overexpressing BCL2 and had a response with a durable remission to venetoclax, a BCL2 inhibitor.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc1808354